Edition:
United States

C R Bard Inc (BCR)

BCR on New York Consolidated

318.53USD
19 Sep 2017
Change (% chg)

$-0.99 (-0.31%)
Prev Close
$319.52
Open
$319.80
Day's High
$320.16
Day's Low
$318.14
Volume
99,882
Avg. Vol
590,771
52-wk High
$324.58
52-wk Low
$203.63

Summary

Name Age Since Current Position

Timothy Ring

59 2003 Chairman of the Board, Chief Executive Officer

John Weiland

61 2016 President, Vice Chairman of the Board, Chief Operating Officer

James Beasley

53 2013 Group President

Timothy Collins

56 2013 Group President

John Groetelaars

50 2015 Group President

Christopher Holland

50 2012 Chief Financial Officer, Senior Vice President

Samrat Khichi

49 2014 Senior Vice President, General Counsel, Secretary

John DeFord

55 2007 Senior Vice President - Science, Technology and Clinical Affairs

Frank Lupisella

56 2006 Vice President, Controller

Betty Larson

41 2014 Vice President - Human Resources

Sharon Luboff

54 2009 Group Vice President

Gerard Porreca

53 2016 Vice President - Quality, Regulatory and Medical Affairs

David Barrett

74 2009 Independent Director

Robert Davis

50 2016 Independent Director

Herbert Henkel

68 2014 Independent Director

John Kelly

74 2009 Independent Director

David Melcher

62 2016 Independent Director

Gail Naughton

61 2004 Independent Director

Tommy Thompson

75 2005 Independent Director

Anthony Welters

62 1999 Independent Director

Tony White

70 1996 Independent Director

Todd Garner

Vice President - Investor Relations

Biographies

Name Description

Timothy Ring

Mr. Timothy M. Ring is Chairman of the Board, Chief Executive Officer of the Company. Mr. Ring has served as Chairman and Chief Executive Officer of the Company since August 2003, having been Group President from April 1997 to August 2003, Group Vice President from December 1993 to April 1997 and Vice President-Human Resources from June 1992 to December 1993. He is also a director of Quest Diagnostics Incorporated. Mr. Ring has been nominated to serve an additional term as a director due to his prior service on C. R. Bard’s Board and more than 20 years of experience in various leadership capacities at C. R. Bard, including as the Company’s Chairman and Chief Executive Officer. He was previously responsible for the Company’s global Vascular and Specialty Access businesses. Mr. Ring has been instrumental in developing and implementing C. R. Bard’s current strategic direction. Prior to joining the Company, he gained valuable experience in leadership roles at Abbott Laboratories in both human resources and general management. Mr. Ring is a Trustee of the Foundation of The University of Medicine & Dentistry of New Jersey. He holds a B.S. in Industrial and Labor Relations from Cornell University.

John Weiland

Mr. John H. Weiland is President, Vice Chairman of the Board, Chief Operating Officer of the Company. Mr. Weiland was elected as Vice Chairman in August 2016 and has served as President and Chief Operating Officer of the Company since August 2003, having been Group President from April 1997 to August 2003 and Group Vice President from March 1996 to April 1997. Mr. Weiland joined C. R. Bard from Dentsply International, where he was a Senior Vice President, until March 1996. He is also a director of West Pharmaceutical Services, Inc. Mr. Weiland has been nominated to serve an additional term as a director as a result of his extensive knowledge and experience in the medical device industry, his prior service on C. R. Bard’s Board, and more than 20 years of experience in various leadership capacities at the Company. Mr. Weiland joined C. R. Bard in 1996 as Group Vice President and was promoted to Group President in 1997, with responsibility for C. R. Bard’s Surgical, Urological and Endoscopic Technology businesses, and its worldwide manufacturing operations. He was promoted to President and Chief Operating Officer in August 2003. Mr. Weiland also held senior management positions at Dentsply International, American Hospital Supply and Baxter Healthcare. In 1987, he was named a White House Fellow and served as a Special Assistant to two members of President Reagan’s cabinet. Mr. Weiland is a 2012 recipient of the prestigious Horatio Alger Award and serves as a director of the Horatio Alger Association. Mr. Weiland received a B.S. in Biology from DeSales University and an M.B.A. from New York University.

James Beasley

Mr. James C. Beasley is Group President of the Company. He joined Bard in 1989 as a territory sales manager for Bard Interventional Products. He has held a succession of management positions including President of Bard Access Systems division from 2003 to 2007 and President of Bard Peripheral Vascular division from 2007 to 2012. In 2009, Mr. Beasley was promoted to Group Vice President and assumed responsibility for both divisions. From January 2012 to July 2013, Mr. Beasley also had responsibilities for Bard’s businesses in Japan, Asia (excluding China) and Australia. In July 2013, Mr. Beasley was promoted to Group President and assumed responsibilities for Bard’s businesses in Latin America while continuing to be responsible for the Bard Access Systems (through June 2015) and Bard Peripheral Vascular divisions, and Bard’s business in Japan. In July 2015, He assumed additional responsibilities for driving a new market development process across Bard to enable and accelerate the company’s growth in new and developing markets.

Timothy Collins

Mr. Timothy P. Collins is Group President of the Company. He joined Bard in 1986 as a facilities planner with the USCI division. Over the next 12 years, Mr. Collins held positions of increasing responsibility including Director of Operations for Diagnostic Cardiology. Concurrent with the sale of Bard’s cardiology business, Mr. Collins joined Medtronic Vascular in 1998 as Vice President/Business Unit Manager in Medtronic/AVE and was later appointed Vice President, Global Operations, Vascular. Mr. Collins returned to Bard and was President of the Bard Electrophysiology division from 2003 to 2008. In 2008, Mr. Collins was promoted to Group Vice President responsible for worldwide manufacturing operations and also assumed responsibility for the Electrophysiology division, until its sale in November 2013. In January 2012, Mr. Collins assumed additional responsibility for Bard’s businesses in Canada. In July 2013, Mr. Collins was promoted to Group President and assumed additional responsibility for Bard’s businesses in Europe. In July 2015, Mr. Collins assumed additional responsibilities for Bard Medical division.

John Groetelaars

Mr. John P. Groetelaars is Group President of the Company. Mr. Groetelaars joined Bard in 2008 as Vice President and General Manager of the Davol division. Mr. Groetelaars was President of the Davol division from 2009 to 2013. In July 2013, Mr. Groetelaars was promoted to Group Vice President and assumed additional responsibilities for Bard’s businesses in China, Asia and Australia while continuing to be responsible for Bard’s Davol division. In July 2015, Mr. Groetelaars was promoted to Group President and added Bard Access Systems to his current responsibilities. Prior to joining Bard, Mr. Groetelaars held positions of increasing responsibility with Boston Scientific Corporation from 2001 until joining Bard and having most recently served as General Manager and Vice President for UK, Ireland and Nordic Regions.

Christopher Holland

Mr. Christopher S. Holland is Chief Financial Officer, Senior Vice President of the Company. He joined Bard in 2012 as Senior Vice President and Chief Financial Officer. From July 2013 through June 2015, Mr. Holland had responsibility for Bard Medical division. In July 2015, Mr. Holland assumed responsibilities for Business Development, Corporate Marketing, Reimbursement, Healthcare Economics and Strategy. Prior to joining Bard, he held executive positions at ARAMARK Corporation since 2003 and was most recently Senior Vice President, Finance and Treasurer. Previously, Mr. Holland held various positions at J.P. Morgan and Company, Inc., including Vice President, with responsibility for the medical device sector.

Samrat Khichi

Mr. Samrat S. Khichi is Senior Vice President, General Counsel, Secretary of the Company. Mr. Khichi joined Bard in July 2014 as Senior Vice President, General Counsel and Secretary. Prior to joining Bard, Mr. Khichi was Chief Administrative Officer, Senior Vice President, General Counsel and Secretary at Catalent Pharma Solutions, Inc, a portfolio company of The Blackstone Group, since 2007. Previously, Mr. Khichi served as Counsel, Mergers and Acquisition and Private Equity for O’Melveny & Myers LLP.

John DeFord

Dr. John A. DeFord, Ph.D., is Senior Vice President-Science, Technology and Clinical Affairs of Company. Dr. DeFord joined Bard in 2004 as Vice President, Science & Technology after serving as Managing Director with Early Stage Partners, LLP (ESP), a venture capital fund, from 2002 until 2004. Before joining ESP he was President and CEO of Cook Incorporated, a privately-held medical device Company. He was promoted to Senior Vice President-Science, Technology & Clinical Affairs in 2007.

Frank Lupisella

Mr. Frank Lupisella Jr., is Vice President, Controller of the Company. Mr. Lupisella joined Bard in 1987 and has served in various capacities in the finance organization of the company. Mr. Lupisella served as Vice President and Controller of the Davol division from 1999 until 2005 when he was promoted to Assistant Corporate Controller, Manufacturing Operations. In 2006, he was promoted to his present position of Vice President and Controller of the company.

Betty Larson

Ms. Betty D. Larson is Vice President - Human Resources of the Company. Ms. Larson joined Bard in September 2014 as Vice President, Human Resources. Prior to joining Bard, She held positions of increasing responsibility with Baxter Healthcare Corporation from 1999 until joining Bard and having most recently served as Vice President, Human Resources – Global Medical Products Business.

Sharon Luboff

Ms. Sharon M. Luboff is Group Vice President of the Company. She joined Bard in 2004 as President of Bard Medical division. Ms. Luboff was promoted to Group Vice President and was responsible for Bard’s international businesses from 2009 to 2013 and for Bard Medical division from 2012 to 2013. In July 2013, Ms. Luboff assumed responsibility for Corporate Marketing, Reimbursement, Healthcare Economics and Business Development and Strategy. Prior to joining Bard, she held positions at Baxter Healthcare including Vice President, Global Therapeutic Marketing for its Renal Division.

Gerard Porreca

Mr. Gerard D. Porreca III is Vice President - Quality, Regulatory and Medical Affairs of the Company. Prior to joining Bard, Mr. Porreca was Senior Vice President, Global Regulatory Affairs and Quality Assurance and Chief RA/QA Officer at Smith and Nephew PLC since 2011.

David Barrett

Dr. David M. Barrett, M.D. is Independent Director of the Company. He is Emeritus President and Chief Executive Officer of Lahey Clinic (a nonprofit, multispecialty healthcare organization). Dr. Barrett retired from his position as President and CEO of Lahey Clinic having served in this role from September 1999 to November 2010 and as a member of its Board of Trustees and Chair of the Board of Governors from September 1999 to November 2010, having been Chair of the Department of Urology of the Mayo Clinic, Vice Chair of the Board of Governors, Trustee of the Mayo Foundation and a member of its Executive Committee since 1975. He is Emeritus Anson L. Clark Professor of Urology at the Mayo Clinic Medical School and currently Clinical Professor of Surgery at Dartmouth Medical School. Dr. Barrett is an Emeritus Trustee of the Lahey Clinic and the Mayo Clinic. Dr. Barrett served as a flight surgeon in the U.S. Air Force. Dr. Barrett was formerly a director of ProUroCare Medical, Inc. Dr. Barrett has been nominated to serve an additional term as a director as a result of, among other things, the breadth of healthcare experience that he brings to C. R. Bard. As President and Chief Executive Officer of Lahey Clinic, Dr. Barrett oversaw one of the largest healthcare systems in New England. He also currently serves on the executive and compensation committees and as chair of the governance committee of the CommonFund, an institutional investment firm that works with the nonprofit and pension investment communities. Dr. Barrett also serves as a director of AdvantEdge Health Solutions, a privately-held medical billing company. In addition, before joining Lahey Clinic in September 1999, he had a distinguished career as a physician, teacher and administrator at the Mayo Clinic. Dr. Barrett is an authority on urologic oncology, urinary incontinence, bladder reconstruction and genitourinary prostheses. He is the former president of the Urodynamic Society, the American Board of Urology and the American Association of Genitourin

Robert Davis

Mr. Robert M. Davis is an Independent Director of the Company. He is Executive Vice President and Chief Financial Officer of Merck & Co., Inc. (“Merck”) (global health care company) since April 2014. Prior to that, Mr. Davis served as Corporate Vice President and President of Baxter Renal Division from June 2010 to October 2010 and Corporate Vice President and President of Baxter Medical Products from October 2010 to April 2014, having been Corporate Vice President and Chief Financial Officer of Baxter Healthcare from May 2006 to June 2010, and Treasurer of Baxter Healthcare from November 2004 to May 2006. He also served as Director of Corporate Financial Planning of Eli Lilly and Company from 2002 to 2004, and as Assistant Treasurer and various financial positions at Eli Lilly and Company from 1990 to 2002. Mr. Davis has been nominated to serve as a director as a result of, among other things, his significant experience in management, strategy, business development, finance, accounting for public companies and technical operations for global companies. This experience includes his service as the Chief Financial Officer of Merck, as well as his prior experience gained in a variety of management and finance roles at Baxter International. He holds both a B.S. in business from Miami University in Ohio, as well as an M.B.A. and a J.D. from Northwestern University in Chicago.

Herbert Henkel

Mr. Herbert L. Henkel is an Independent Director of the Company. He is Retired Chairman and Chief Executive Officer of Ingersoll-Rand Company (a global diversified industrial company). Mr. Henkel served as Chairman from February 2010 to June 2010, having been Chairman and Chief Executive Officer from May 2000 to February 2010, President and Chief Executive Officer from October 1999 to May 2000 and President and Chief Operating Officer from April to October 1999. Prior to that, Mr. Henkel served as President and Chief Operating Officer of Textron, Inc. from 1998 to 1999, having been President of Textron Industrial Products from 1995 to 1998. He is also a director of 3M Company, Allstate Corporation and Herc Holdings Inc. Mr. Henkel was formerly a director of Visteon Corporation. Mr. Henkel served as lead director from January 1, 2011 until June 30, 2014. Mr. Henkel has been nominated to serve an additional term as a director as a result of the breadth and significance of his experience in management, sales and marketing, as well as research and technical operations for global companies in a variety of industries. This experience includes his service as the Chairman and Chief Executive Officer of Ingersoll-Rand Company, a global diversified industrial company, as well as his prior service on C. R. Bard’s Board and experience on the audit, governance and nominating committees of other large public companies. He holds both a B.S. and an M.S. in engineering from Polytechnic University of New York, as well as an M.B.A. from Pace University, New York.

John Kelly

Mr. John C. Kelly is Independent Director of the Company. He is Former Senior Vice President, Finance of Pfizer Inc. (pharmaceutical products). Mr. Kelly served as Senior Vice President, Finance of Pfizer Inc. from October 2009 to February 2010, having been Vice President and Controller of Wyeth (pharmaceutical and healthcare products) since March 2008. Mr. Kelly held various other positions, including Vice President, Finance Operations, since joining Wyeth in 2002. He is also a director of The Medicines Company. Mr. Kelly has been nominated to serve an additional term as a director as a result of over 45 years of experience in accounting and finance, as well as his background in healthcare. Prior to joining Wyeth (and then Pfizer), where he handled a wide range of assignments in finance, he spent more than 35 years in public accounting at Arthur Andersen in various leadership capacities, including as the partner in charge of audit and business consulting practices in the New York metropolitan area. He is a certified public accountant and was an elected member of the Council of the American Institute of Certified Public Accountants. He earned both his B.S. in business administration and M.B.A. in international finance from Seton Hall University.

David Melcher

Lt. Gen. David F. Melcher is an Independent Director of the Company. He is President and Chief Executive Officer of Aerospace Industries Association (a trade association representing major aerospace and defense manufacturers and suppliers) since June 2015. Prior to that, Lieutenant General (Ret.) Melcher served as Chief Executive Officer, President and member of the Board of Directors of Exelis Inc. (a diversified, global aerospace defense, information and technology services company) from November 2011 to May 2015, having been President of ITT Defense & Information Solutions from December 2008 until the spin-off of Exelis Inc. from ITT in October 2011. Mr. Melcher also served as Vice President of Strategy and Business Development for ITT Defense & Information Solutions from August 2008 to December 2008, following 32 years of distinguished service in the U.S. Army. He currently serves on the Executive Committee and Board of Governors of the Aerospace Industries Association. Mr. Melcher has been nominated to serve an additional term as a director as a result of his significant leadership in program management, strategy development and finance, as well as extensive international strategic business, budget and policymaking experience gained during more than 25 years of leadership positions in the defense community, including his role as Chief Executive Officer and President of Exelis Inc. He has also demonstrated leadership and management experience with the U.S. Army, having served as the Army’s Military Deputy for Budget and Deputy Chief of Staff for Programs in the Pentagon, and as Commander of the Corps of Engineers, Southwestern Division in Dallas, Texas. He is a 2014 recipient of the Association of the United States Army John W. Dixon award for contributions to the Defense Industry.

Gail Naughton

Dr. Gail K. Naughton, Ph.D. is Independent Director of the Company. She is Chairman and Chief Executive Officer of Histogen, Inc. (regenerative medicine). Dr. Naughton has served as the Chairman and Chief Executive Officer of Histogen, Inc. since June 2007, having been Vice Chairman of Advanced Tissue Sciences, Inc. (ATS) (human-based tissue engineering) from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and Co-Founder and Director since inception in 1991. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. She is also a director of Cytori Therapeutics, Inc. Dr. Naughton has been nominated to serve an additional term as a director because of the breadth of her life sciences industry knowledge and experience, including her experience as Chairman and Chief Executive Officer of Histogen, Inc. Dr. Naughton was the first woman to be awarded the National Inventor of the Year award by The Intellectual Property Owners Association. She has conducted extensive research, authored numerous scientific publications and holds more than 95 U.S. and foreign patents. Dr. Naughton has also built a distinguished academic career, including serving as the Dean of the College of Business Administration, San Diego State University and on the boards of several academic institutions, non-profit organizations and foundations. Dr. Naughton earned a B.S. from St. Francis College, Brooklyn, New York, and both an M.S. in Histology and a Ph.D. in Hematology from New York University Medical Center. She also holds an M.B.A. in Executive Management from the Anderson School at the University of California, Los Angeles.

Tommy Thompson

Gov. Hon. Tommy G. Thompson, J.D., is Independent Director of the Company. He is Former Secretary of the U.S. Department of Health and Human Services. Mr. Thompson served as Secretary of the U.S. Department of Health and Human Services from January 2001 to January 2005, having been Governor of Wisconsin from November 1986 to January 2001. He is also Chairman and Chief Executive Officer of Thompson Holdings (a consulting firm) since 2012. Mr. Thompson also serves as an adjunct senior advisor at the Akin Gump Strauss Hauer & Feld LLP law firm since January 2017, having been a partner of the law firm from March 2005 to January 2012. He served as Independent Chairman of the Deloitte Center for Health Solutions from March 2005 to May 2009. Mr. Thompson was Chairman of the Board of Logistics Health, Inc. from January 2011 to June 2011, having been President of Logistics Health, Inc. from February 2005 to January 2011. He is also a director of Centene Corporation, Physicians Realty Trust, United Therapeutics Corporation and Therapeutics MD, Inc. Mr. Thompson was formerly a director of Cancer Genetics, Inc., CareView Communications, Inc., Cytori Therapeutics, Inc., PURE Bioscience, SpectraScience, Inc. and Tyme Technologies, Inc. Mr. Thompson has been nominated to serve an additional term as a director as a result of his significant experience in the healthcare industry, both as a public official and in the private sector. As Secretary of the U.S. Department of Health and Human Services, he oversaw the principal public agency for protecting the health of Americans and providing essential human services through its eleven divisions, including the U.S. Food and Drug Administration, the Office of Inspector General, the Center for Medicare and Medicaid Services, and the Centers for Disease Control and Prevention.

Anthony Welters

Mr. Anthony Welters is Independent Director of the Company. He is Executive Chairman of BlackIvy Group, LLC (a private investment company focused on investments in Sub-Saharan Africa) since January 2013. Mr. Welters served as Senior Advisor to the Chief Executive Officer of UnitedHealth Group, Inc. (a diversified health and well-being company) from January 2013 to January 2016, having served as Executive Vice President of UnitedHealth Group, Inc. from November 2006 to January 2013 and as a Member of the Office of the Chief Executive Officer from January 2011 to January 2013. He also served as President of the Public and Senior Markets Group from September 2007 to December 2010. Mr. Welters has also served as President and Chief Executive Officer of AmeriChoice Corporation, a UnitedHealth Group Company, and Chairman and Chief Executive Officer of AmeriChoice Corporation and its predecessor companies from 1989 until its acquisition by UnitedHealth Group. He is also a director of Loews Corporation and The Carlyle Group. Mr. Welters has been nominated to serve an additional term as a director as a result of over 25 years of experience in the healthcare industry and his prior service on C. R. Bard’s Board. This experience includes his service as Executive Vice President of UnitedHealth Group, which designs products, provides services and applies technologies designed to improve access to health and well-being services. He is a recipient of the prestigious Horatio Alger Award and serves as a director of the Horatio Alger Association. He is also Emeritus Chairman of the Board of Trustees for the Morehouse School of Medicine in Atlanta. Mr. Welters holds a B.A. from Manhattanville College and a J.D. from New York University School of Law.

Tony White

Mr. Tony Lee White is Independent Director of the Company. He is Retired Chairman, President and Chief Executive Officer of Applied Biosystems, Inc. (formerly Applera Corporation). Mr. White served as Chairman, President and Chief Executive Officer of Applied Biosystems, Inc. from September 1995 through November 2008. He is also a director of CVS Health Corp. and Ingersoll-Rand Company. Mr. White was appointed as lead director effective July 2014. Mr. White has been nominated to serve an additional term as a director as a result of his significant experience in the life sciences industry. His experience includes his service as Chairman, President and Chief Executive Officer of Applied Biosystems, Inc., a life sciences and products company, as well as his prior service on C. R. Bard’s Board and experience on both the executive and compensation committees of other large public companies. He also held a number of management positions both in the United States and internationally during a 26-year career at Baxter International, Inc. Mr. White received his B.A. from Western Carolina University.

Todd Garner